Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
14 May, 2026
Review highlights vital need for RTQA in radiation therapy research
LATEST NEWS: 14 May 2026 The need for greater
14 April, 2026
Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices
LATEST NEWS: 14 April 2026 TROG has made a